Prospective Memory in Parkinson's Disease - Full Text View

Prospective Memory in Parkinson's Disease (ProMem)

This study has been completed.

First Received: June 1, 2009 Last Updated: July 14, 2009 History of Changes

Sponsors and Collaborators:	Washington University School of Medicine National Institutes of Health (NIH)
Information provided by:	Washington University School of Medicine
ClinicalTrials.gov Identifier:	NCT00913640

Purpose

The investigators tested whether prospective memory is impaired in individuals with Parkinson's Disease compared to controls using reliable and validated experimental measures. Also, the investigators assessed the impact of Parkinson's medication on prospective memory performance in PD to better estimate prospective memory function in PD patients' everyday (chronically treated) life.

Condition
Memory Prospective Memory Parkinson's Disease

Study Type:	Observational
Study Design:	Case Control, Cross-Sectional
Official Title:	Prospective Memory in Parkinson's Disease

Resource links provided by NLM:

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics: Memory Parkinson's Disease

U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:

Prospective Memory [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Groups/Cohorts
PD Group
Control Group

Eligibility

Ages Eligible for Study:	40 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Community Movement Disorder Clinic at Washington University St. Louis

Criteria

Inclusion Criteria:

PD Group:
- Clinically definite PD
- 40-70 years old
- Hoehn and Yahr stage I,II,III
- Currently treated with Levodopa/carbidopa
Control Group:
- 40-70 years old
- Spouses of PD Group preferred

Exclusion Criteria:

PD Group and Control Group:
- Significant neurological problems
- Significant current psychiatric diagnoses
- Mini Mental Status Exam score < 24 (MMSE)
- Any significant abnormality on brain imaging
- MPTP exposure
- Control Participants met the same exclusion criteria described above as well as a biological family history of PD

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00913640

Locations

United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110

Sponsors and Collaborators

Washington University School of Medicine

National Institutes of Health (NIH)

Investigators

Principal Investigator:

Tamara G Hershey, Ph.D.

Washington University School of Medicine

More Information

Additional Information:

Link to Dr. Hershey's Web Site This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Washington University ( Tamara G Hershey PhD., )
Study ID Numbers:	05-0203
Study First Received:	June 1, 2009
Last Updated:	July 14, 2009
ClinicalTrials.gov Identifier:	NCT00913640 History of Changes
Health Authority:	United States: Institutional Review Board

Keywords provided by Washington University School of Medicine:

Prospective Memory Performance
Prospective Memory Outcome
Parkinson's Disease

Study placed in the following topic categories:

Ganglion Cysts
Movement Disorders
Parkinson Disease
Basal Ganglia Diseases

Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

Additional relevant MeSH terms:

Movement Disorders
Parkinson Disease
Nervous System Diseases
Basal Ganglia Diseases

Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

ClinicalTrials.gov processed this record on September 10, 2009